ABT Stock Recent News

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 250 points on Wednesday.

Abbott Laboratories (NYSE:ABT ) Q4 2024 Earnings Conference Call January 22, 2025 9:30 AM ET Company Participants Mike Comilla - Vice President, Investor Relations Robert Ford - Chairman & Chief Executive Officer Phil Boudreau - Executive Vice President, Finance & Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Travis Steed - BofA Securities Vijay Kumar - Evercore ISI Josh Jennings - TD Cowen David Roman - Goldman Sachs Joanne Wuensch - Citi Danielle Antalffy - UBS Matt Miksic - Barclays Operator Good morning and thank you for standing by. Welcome to Abbott's Fourth Quarter 2024 Earnings Conference Call.

The headline numbers for Abbott (ABT) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

On Wednesday, Abbott Laboratories ABT reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion.

Abbott (ABT) came out with quarterly earnings of $1.34 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $1.19 per share a year ago.

Abbott Laboratories posts total worldwide sales of $10.97 billion for the quarter ended Dec. 31, missing Wall Street estimates of $11.03 billion.

Abbott Laboratories on Wednesday forecast annual profit in line with Wall Street estimates, as it expects elevated medtech-related procedures to boost demand for its devices, including glucose-monitoring products.

Fourth-quarter sales of $11.0 billion; full-year 2024 sales of $42.0 billion Fourth-quarter reported sales increased 7.2 percent; organic sales growth for the underlying base business increased 10.1 percent1 Full-year 2024 reported sales increased 4.6 percent; organic sales growth for the underlying base business increased 9.6 percent2 Abbott projects full-year 2025 organic sales growth to be in the range of 7.5% to 8.5% ABBOTT PARK, Ill., Jan. 22, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2024.

When most of us think of investing in stocks, we think of the potential gains -- or unfortunately, in some cases, losses -- that might follow. A particular stock will rise or fall, and we'll benefit or lose.

Investors interested in Medical - Products stocks are likely familiar with Haemonetics (HAE) and Abbott (ABT). But which of these two companies is the best option for those looking for undervalued stocks?